Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Long COVID Syndrome (Long COVID), Post Acute COVID-19 Syndrome (PACS) or Post COVID-19
Syndrome (PCS) is defined as 'signs and symptoms that develop during or following an
infection consistent with COVID-19, continue for more than 12 weeks and are not explained by
an alternative diagnosis'. 1 in 10 infected individuals may suffer persistent symptoms, and
we are facing an emerging problem that will severely affect individuals, health care systems
and society for years to come.
We explore hyperbaric oxygen administered in a randomized placebo-controlled clinical trial
as a potential treatment for patients suffering from Long COVID.
The overall hypothesis to be evaluated is that hyperbaric oxygen (HBO2) alleviates symptoms
associated with Long COVID.
Phase:
Phase 2
Details
Lead Sponsor:
Karolinska University Hospital
Collaborators:
EDC Scandinavia AB Karolinska Institutet Karolinska Trial Alliance